Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 52

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 52
---
off                    |     |     | 56 |     | Chief Executive Officer                               |
| James Burns                   |     |     | 47 |     | Chief Legal Officer                                   |
| Cecilia Jones                 |     |     | 50 |     | Chief Financial Officer                               |
| Sarah Gheuens, M.D., Ph.D.    |     |     | 46 |     | Chief Medical Officer, Head of Research & Development |
| Tsveta Milanova               |     |     | 48 |     | Chief Commercial Officer                              |
| Krishnan Viswanadhan, Pharm.D |     |     | 46 |     | Chief Corporate Development & Strategy Officer        |

The biography of Mr. Goff can be found under “Members of the Board of Directors Continuing in Office.” James Burnshas served as our chief legal officer since January 2022. Mr. Burns joined Agios in 2016 as a senior attorney and the first head of compliance, after which he served as Senior Vice President and General Counsel. Mr. Burns has more than 18 years of legal and compliance experience in the pharmaceutical industry. Prior to joining Agios, Mr. Burns held roles of increasing responsibility at EMD Serono Inc., a biotechnology company, culminating in his position as associate general counsel for commercial. Mr. Burns began his legal career as a corporate attorney at Testa, Hurwitz and Thibeault LLP and Goodwin Procter LLP. Mr. Burns holds a B.A. degree from Seton Hall University and a J.D. from Seton Hall University School of Law. Cecilia Joneshas served as our chief financial officer since September 2022. Prior to joining Agios, Ms. Jones served as Chief Financial Officer of LogicBio Therapeutics, Inc., or LogicBio, a gene therapy company, from January 2021 to September 2022. Prior to joining LogicBio, Ms. Jones worked at Biogen, where she held a variety of roles beginning in November 2010, most recently serving as Vice President, Finance from June 2019 until January 2021 and as Senior Director, Corporate Finance from July 2015 to June 2019. Before Biogen, Ms. Jones served in various roles in financial planning and analysis at Interactive Data Corporation, a financial market data company, and Genzyme Corporation (prior to its acquisition by Sanofi S.A.). Ms. Jones has an M.B.A. from the Harvard Business School and an economics degree from Universidad de